首页> 外文OA文献 >Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

【2h】

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

机译：嵌合抗原受体T细胞疗法在复发/难治性大B细胞淋巴瘤中较旧的脆弱患者的影响和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Richard J. Lin; Stephanie M. Lobaugh; Martina Pennisi; Hei Ton Chan; Yakup Batlevi; Theresa A. Elko; Molly A. Maloy; Connie L. Batlevi; Parastoo B. Dahi; Sergio A. Giralt; Paul A. Hamlin; Elena Mead; Arela Noy; Bianca D. Santomasso; Craig S. Sauter; Michael Scordo; Gunjan L. Shah; Beatriz Korc-Grodzicki; Soo Jung Kim; Mari Lynne Silverberg; Chelsea A. Brooklyn; Sean M. Devlin; Miguel-Angel Perales;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy [J] . Jin Aiyun, Feng Jingjing, Wang Zhudan, Bone marrow transplantation . 2019,第7期

机译：嵌合抗原受体T细胞疗法复发/难治性B细胞淋巴瘤患者中颈淋巴结快速扩大的严重呼吸困难
2. Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas [J] . Chong Elise A., Svoboda Jakub, Nasta Sunita Dwivedy, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：顺序抗CD19定向嵌合抗原受体修饰的T细胞疗法（CART19）和PD-1与PEMBROLIZUAB的患者复发或难治性B细胞非霍奇金淋巴瘤患者
3. Repeat Infusion of CD19-Specific Chimeric Antigen Receptor T-Cell Could Improve the Efficacy with Consistent Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [J] . Hu Jianda, Yang Ting, Yang Xiaozhu, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：CD19特异性嵌合抗原受体T细胞的重复输注可以提高复发/难治弥漫性大B细胞淋巴瘤的一致安全性
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Impact and safety of chimeric antigen receptor T-cell therapy in older vulnerable patients with relapsed/refractory large B-cell lymphoma [O] . Richard J. Lin, Stephanie M. Lobaugh, Martina Pennisi, 2021

机译：嵌合抗原受体T细胞疗法在复发/难治性大B细胞淋巴瘤中较旧的脆弱患者的影响和安全性
7. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma [O] . Gary H. Lyman, Andy Nguyen, Sophie Snyder, 2020

机译：复发或难治性大B细胞淋巴瘤患者患者嵌合抗原受体T细胞治疗的经济评价

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅